These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 11361510

  • 1. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children.
    Allen UD, Kirby MA, Goeree R.
    Pediatr AIDS HIV Infect; 1997 Feb; 8(1):4-11. PubMed ID: 11361510
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP, Abels RI, McNeill MV, Sullivan DJ.
    Arch Intern Med; 1993 Dec 13; 153(23):2669-75. PubMed ID: 8250662
    [Abstract] [Full Text] [Related]

  • 3. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes.
    Vitale MG, Roye BD, Ruchelsman DE, Roye DP.
    Spine J; 2007 Dec 13; 7(3):292-300. PubMed ID: 17482112
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
    Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, Fiala M, Fischl MA, Gabin SJ, Gottlieb MS.
    Ann Intern Med; 1992 Nov 01; 117(9):739-48. PubMed ID: 1416576
    [Abstract] [Full Text] [Related]

  • 5. Anemia therapy: individual benefit and societal cost.
    Denton TA, Diamond GA, Matloff JM, Gray RJ.
    Semin Oncol; 1994 Apr 01; 21(2 Suppl 3):29-35. PubMed ID: 8202723
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM, Tsevat J.
    Med Decis Making; 2004 Apr 01; 24(1):30-9. PubMed ID: 15005952
    [Abstract] [Full Text] [Related]

  • 7. Important cost differences of blood transfusions and erythropoietin between hemodialysis and peritoneal dialysis patients.
    Pagé DE, House A.
    Adv Perit Dial; 1998 Apr 01; 14():87-9. PubMed ID: 10649699
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
    MacLaren R, Sullivan PW.
    Value Health; 2005 Apr 01; 8(2):105-16. PubMed ID: 15804319
    [Abstract] [Full Text] [Related]

  • 9. Financial impact of the introduction of erythropoietin in the treatment of anemia of premature infants in Israel.
    Dollberg S, Mimouni FB.
    Isr Med Assoc J; 1999 Oct 01; 1(2):86-8. PubMed ID: 10731302
    [Abstract] [Full Text] [Related]

  • 10. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin.
    Barlogie B.
    Semin Hematol; 1993 Oct 01; 30(4 Suppl 6):25-7. PubMed ID: 8153675
    [Abstract] [Full Text] [Related]

  • 11. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia.
    Sheffield R, Sullivan SD, Saltiel E, Nishimura L.
    Ann Pharmacother; 1997 Jan 01; 31(1):15-22. PubMed ID: 8997459
    [Abstract] [Full Text] [Related]

  • 12. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H, de Lissovoy G, Hollenbeak C, Custer B, Hofmann A, McClellan W, Gitlin M.
    J Med Econ; 2012 Jan 01; 15(2):293-304. PubMed ID: 22115328
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer.
    Henry DH.
    Semin Hematol; 1993 Oct 01; 30(4 Suppl 6):12-6. PubMed ID: 8153671
    [Abstract] [Full Text] [Related]

  • 14. Human immunodeficiency virus infection, anemia, and survival.
    Moore RD.
    Clin Infect Dis; 1999 Jul 01; 29(1):44-9. PubMed ID: 10433563
    [Abstract] [Full Text] [Related]

  • 15. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.
    Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM.
    J Pain Symptom Manage; 2004 Feb 01; 27(2):185-90. PubMed ID: 15157043
    [Abstract] [Full Text] [Related]

  • 16. [Erythropoietin treatment of anemia associated with human immunodeficiency virus infection].
    Moreno García M.
    Med Clin (Barc); 1997 Feb 22; 108(7):266-71. PubMed ID: 9121196
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of competing strategies for the treatment of pediatric empyema.
    Cohen E, Weinstein M, Fisman DN.
    Pediatrics; 2008 May 22; 121(5):e1250-7. PubMed ID: 18450867
    [Abstract] [Full Text] [Related]

  • 18. Optimizing the approach to anemia in the preterm infant: is there a role for erythropoietin therapy?
    Asch J, Wedgwood JF.
    J Perinatol; 1997 May 22; 17(4):276-82. PubMed ID: 9280091
    [Abstract] [Full Text] [Related]

  • 19. The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
    Devine EB, Cross JT, Kowdley KV, Sullivan SD.
    Curr Med Res Opin; 2007 Jun 22; 23(6):1463-72. PubMed ID: 17559739
    [Abstract] [Full Text] [Related]

  • 20. [HuEPO treatment of anemia in preterm infants].
    Galligani L, Perona A.
    Minerva Pediatr; 1994 Nov 22; 46(11):521-6. PubMed ID: 7870011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.